Stomach cancer
Stomach cancer, also called gastric cancer, is a malignant disease arising in the stomach.
Stomach cancer, also called gastric cancer, is a malignant disease arising in the stomach. The term includes several histological entities, with adenocarcinoma being a major focus of contemporary clinical and translational research. Its biological and clinical behavior is studied through tumor-cell proliferation, apoptosis, migration, metastasis, the tumor microenvironment, and interactions with immune populations such as CD8-positive T-cells.
Management research spans gastrectomy, chemotherapy, immunotherapy, and checkpoint inhibitor strategies, with treatment selection increasingly informed by biomarkers and prognosis. Current investigations also examine Helicobacter pylori as a preventable risk factor, fluorouracil-containing regimens, patient-derived organoids, radiomics, extracellular-vesicle proteins, cancer stem-like cells, and immune-related molecular targets. Depending on study design, outcomes may be evaluated using survival, hazard ratio, Cox proportional hazards models, sensitivity, and Area Under the Curve measurements.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
10 papers study stomach cancer directly. The themes below are drawn from those 10. 1 new direction follows.
-
Gastric Cancer Biomarkers and Therapies : Gastric cancer work links extracellular-vesicle vitronectin and LAMA3, AR, and triaptosis-related genes to prognosis and immune targeting. Preclinical therapy is moving toward fruquintinib plus TAS-102 and platinum agents aimed at cancer stem cells. 5 papers · 50%
-
Neoadjuvant Gastric Cancer Therapy : Treatment planning is combining intensive neoadjuvant approaches, including FLOT before chemoradiotherapy, with patient-derived organoids to support precision selection. The shared goal is individualized multimodal therapy before surgical resection. 2 papers · 20%
-
Others — Gastric Cancer Clinical Studies : Clinical management spans patient education, CT radiomics for histologic differentiation, and Helicobacter pylori eradication to reduce risk. The cluster shares a clinical focus but no single diagnostic, preventive, or treatment direction. 3 papers · 30%
Gastric cancer becomes the subject of an AI health-education service rather than only a disease to treat, measure, or prevent
The health education conversational agent for patients with gastric cancer was developed as an embodied, AI-guided system using the OpenMEDLab 2.0 foundation model and retrieval-augmented generation, then evaluated for accuracy, usability, and user experience among patients and stakeholders 42721321Sep. The set otherwise treats gastric cancer as a disease to prevent, diagnose, prognosticate, or treat; this study instead assigns it a role in the design of an interactive patient-education infrastructure. The resulting direction is not another disease intervention or biomarker, but a patient-facing system intended to deliver and adapt health education within gastric-cancer care.
Recent Findings on stomach cancer
A phase II, single-arm clinical trial investigated induction FLOT chemotherapy followed by neoadjuvant chemoradiotherapy for distal esophageal and proximal gastric adenocarcinoma. The study was designed to evaluate whether intensified preoperative treatment could be used before subsequent surgical management, including potential gastrectomy or related resection procedures 42742872Sep.
Proteomic analysis of extracellular vesicles was used to search for gastric cancer-associated protein biomarkers. Vitronectin and laminin subunit alpha-3 were identified as candidate extracellular-vesicle markers in the study context, extending biomarker research beyond tumor-cell measurements toward circulating or secreted molecular material 42366969Jun.
A health education embodied conversational agent was developed for patients with gastric cancer and other relevant stakeholders. The action research study assessed the agent’s accuracy, usability, and user experience, addressing patient support and communication alongside conventional cancer care such as chemotherapy, immunotherapy, and surgery 42721321Sep.
Medicinal-chemistry research examined chemically stabilized Schiff base compounds as potential platinum-based anticancer stem-cell drugs. The lead compound showed activity against gastric cancer stem-like cells by impairing self-renewal and pluripotency, linking drug development to cancer-cell persistence and treatment resistance rather than only bulk tumor proliferation 42720472Sep.
A study of triaptosis-related genes and cells explored their prognostic significance and biological relevance in gastric cancer. The work used this cell-death-related framework to investigate associations with prognosis and potentially relevant tumor-cell populations; the provided context does not report a definitive clinical validation outcome 42700341Sep.
Clinicians’ knowledge and perceptions of gastric cancer patient-derived organoids were assessed in relation to precision medicine. The study focused on the potential clinical utility of organoid research for treatment selection and individualized therapy, including how such models might inform sensitivity to chemotherapy or other anticancer approaches 42425088Jul.
CT radiomics was investigated as a noninvasive method for predicting histologic differentiation in gastric cancer. The researchers aimed to develop a clinical-radiomics model and examine mechanisms underlying the imaging–pathology relationship. Model development in this area may involve diagnostic discrimination measures such as Area Under the Curve, although the supplied context does not provide the model’s performance values 42507312Jul.
A preclinical study combined fruquintinib with TAS-102 in colorectal cancer and gastric cancer xenograft models. It evaluated combined antitumor activity and investigated possible mechanisms accounting for the combination, placing gastric cancer therapy within a broader comparative framework that includes colorectal cancer 42533327Jul.
Population-level research evaluated the preventive effect of Helicobacter pylori treatment on gastric cancer incidence and mortality across different ages. The study specifically addressed whether treatment-associated risk reduction was observed throughout the age range, connecting infection management with gastric cancer prevention rather than treatment of established metastasis 42019986Apr.
Multi-omics analysis examined androgen receptor (AR) as a potential prognostic factor and immune-related therapeutic target in gastric cancer. The work connects molecular profiling with the tumor microenvironment and immune responses, including areas commonly assessed through interferon gamma signaling, CD8-positive T-cell biology, and checkpoint inhibitor strategies; the supplied context identifies AR as a proposed target but does not provide clinical efficacy results 41890218Mar.
Collectively, these publications extend three major research directions. Biomarker and therapy studies combine proteomics, multi-omics, cancer-stem-cell pharmacology, and combination treatment approaches. Prevention and care studies address Helicobacter pylori treatment, noninvasive imaging classification, and patient education. Neoadjuvant-treatment research evaluates intensified preoperative chemotherapy and chemoradiotherapy, while organoid studies explore tools for tailoring therapy before definitive surgical treatment.
Written from 10 PubMed abstracts, each one cited by PMID above. Published: 2026-09-17. Drafted by language models from published abstracts; not medical advice.